Option Chain

Capricor Therapeutics Inc

CAPRNASDAQ · USD

9.00USD+0.40 (+4.66%)

1110

Capricor Therapeutics Inc (CAPR) Option Chain

Capricor Therapeutics Inc trades at $9.00, up 4.66%, with an IV Rank of 98.02%. This is high versus the past year, and the company carries a market cap of $500M in the Biotechnology industry. On the Nov 13, 2026 chain, the at the money $9.00 strike shows calls at $0.80 / $3.10 and puts at $0.30 / $4.90, both carrying about $2.28 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $7.00 calls, at 743 contracts, and the $8.50 puts, at 140, as of Nov 5, 2026.

Tracking the CAPR option chain helps you see every strike and expiry on Capricor Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CAPR options activity at a glance. Use our scanner to monitor the CAPR option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CAPR stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CAPR options are being actively traded, and where they are not.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
61.05	500	510	1.50	1.00	1.20	3.80	8.00	-6.98	0.40	4.80	0.00	2.60	0	2	38.95
64.10	2	2	2.35	0.50	0.80	4.90	8.50	-1.16	0.85	2.30	0.00	1.58	140	5	35.90
66.88	89	21	1.95	0.00	0.80	3.10	9.00	+4.65	0.30	4.90	0.00	2.60	0	2	33.12
69.44	0	0	2.70	0.00	0.50	4.90	9.50	+10.47	0.80	4.90	0.50	2.35	0	0	30.56
71.78	10,157	252	2.25	0.00	1.50	3.00	10.00	+16.28	1.00	4.90	1.00	1.95	0	0	28.22

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank98.02% High
Market cap (M$)500
52 weeks high-78.70%
52 weeks low190.54%
Analyst recommendationBuy
2.20
Target price$27.00
272.89% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-10
P/E—
Future P/E—
EPS (ttm)-2.45
EPS growth next 5 years—

As of Nov 5, 2026

Browse all Option Chain tickers